Claims for Patent: 12,403,173

Summary for Patent: 12,403,173

Title:	Micafungin compositions
Abstract:	An aqueous pharmaceutical composition suitable for parenteral administration and having enhanced storage stability includes between about 0.1 mg/mL and about 40 mg/mL micafungin; (ii) between about 0.1 mM and 400 mM buffering agent; and (iii) between about 0 mg/mL and about 500 mg/mL tonicity adjusting agent, wherein the pH of the composition is between about 3.0 and 7.0, for example, between about 3.5 and 7.0.
Inventor(s):	Sydney J. Cope, Christine L. Rebbeck, Mark J. Doty
Assignee:	Baxter Healthcare SA , Baxter International Inc
Application Number:	US15/843,634
Patent Claims:	1. A packaged sealed container comprising an aqueous pharmaceutical composition suitable for parenteral administration, the container comprising: an aqueous pharmaceutical composition consisting of: (i) between 0.5 mg/ml and 2.5 mg/ml micafungin sodium; (ii) between 1 mM and 20 mM citrate buffering agent; (iii) between 4 mg/ml and 10 mg/ml sodium chloride; and (iv) water, wherein the pH of the aqueous pharmaceutical composition is between 4.0 and 5.5, and the aqueous pharmaceutical composition is provided in the packaged sealed container, wherein the aqueous pharmaceutical composition is sterile and ready to use without further compounding or processing, and wherein the aqueous pharmaceutical composition has less than 1.5% area total impurities after formulation and storage thereof at room temperature for three weeks, as determined by HPLC analysis. 2. The packaged sealed container according to claim 1, wherein the aqueous pharmaceutical composition has less than 0.5% area total impurities after formulation and storage thereof at −20° C. for 48 weeks, as determined by HPLC analysis. 3. The packaged sealed container according to claim 1, wherein the aqueous pharmaceutical composition is frozen. 4. The packaged sealed container according to claim 1, wherein the sealed container comprises a vial or a syringe. 5. The packaged sealed container according to claim 1, wherein the sealed container comprises a plastic bag or a bottle. 6. The packaged sealed container according to claim 1, wherein the aqueous pharmaceutical composition consists of about 1 mg/ml of the micafungin sodium, about 10 mM of the citrate buffering agent, about 9 mg/ml of the sodium chloride, and the water. 7. The packaged sealed container according to claim 4, consisting of the vial or syringe and the aqueous pharmaceutical composition. 8. The packaged sealed container according to claim 5, consisting of the plastic bag or bottle and the aqueous pharmaceutical composition.